SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Societ...
May 17 2018 - 8:45AM
SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS) today
announced that data from the Company’s ongoing Phase 1/2 study of
galinpepimut-S (GPS) in combination with Bristol Myers Squibb’s
nivolumab in patients with Wilms Tumor 1 + ovarian cancer will be
presented at the upcoming American Society of Clinical Oncology
(ASCO) Annual Meeting being held June 1 - 5, 2018 in Chicago,
Illinois. Additionally, following the positive outcome in
triple negative breast cancer patients (TNBC) from the Phase 2b
trial for NeuVax, SELLAS will be conducting clinical and regulatory
advisory board meetings at ASCO based on the independent Data
Safety Monitoring Board recommendation to expeditiously seek
regulatory guidance by the FDA for the development of NeuVax in
TNBC.
Clinical and immunological data from the ongoing Phase 1/2 GPS
plus nivolumab trial evaluating GPS in patients with recurrent WT1+
ovarian cancer in second or greater clinical remission after
salvage chemotherapy will be presented. Details for the
presentation are as follows:
- Title: A phase I study of concomitant
galinpepimut-s (GPS) in combination with nivolumab (nivo) in
patients (pts) with WT1+ ovarian cancer (OC) in second or third
remission.
- Presenter: Roisin E. O’Cearbhaill, M.D.,
Memorial Sloan Kettering Cancer Center
- Abstract Number: 5553
- Poster Session: Gynecologic Cancer
- Date and Time: June 4, 2018, 1:15PM –
4:45PM CT
- Location: McCormick Place, Hall A
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on
novel cancer immunotherapeutics for a broad range of cancer
indications. SELLAS’ lead product candidate, galinpepimut-S (GPS),
is licensed from Memorial Sloan Kettering Cancer
Center and targets the Wilms Tumor 1 (WT1) protein, which is
present in an array of tumor types. GPS has potential as a
monotherapy or in combination to address a broad spectrum of
hematologic malignancies and solid tumor indications. SELLAS has
Phase 3 clinical trials planned for GPS in two indications, acute
myeloid leukemia (AML) and malignant plural mesothelioma (MPM) and
is also developing GPS as a potential treatment for multiple
myeloma and ovarian cancer. SELLAS has received Orphan Drug
designations from the U.S. Food & Drug
Administration (FDA), as well as the European Medicines
Agency, for GPS in AML, MPM and MM; GPS also received Fast Track
designation for AML and MPM from the FDA. SELLAS’ second
product candidate, NeuVax™ (nelipepimut-S), is a first-in-class,
HER2-directed cancer immunotherapy being investigated for the
prevention of the recurrence of breast cancer after standard of
care treatment in the adjuvant setting.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor Contact:Will O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
David Moser, JDSELLAS Life Sciences Group,
Inc.813-864-2571info@sellaslife.com
Source: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024